| Literature DB >> 35456361 |
Tadatsugu Morimoto1, Hirohito Hirata1, Koji Otani2, Eiichiro Nakamura3, Naohisa Miyakoshi4, Yoshinori Terashima5, Kanichiro Wada6, Takaomi Kobayashi1, Masatoshi Murayama1, Masatsugu Tsukamoto1, Masaaki Mawatari1.
Abstract
Many cases of vertebral osteomyelitis (VO) and infective endocarditis (IE) co-infection have been reported, and it has been recognized that attention should be paid to the possibility of both diseases co-existing during diagnosis and treatment. However, the incidence, clinical status, and outcomes of IE in patients with VO remain unclear. For this study, the eligibility criteria for patient recruitment included all cases of VO at the five medical university hospitals. Patients with a history of spinal surgery were excluded from this study. Echocardiography was routinely performed for all patients with VO. IE was diagnosed according to the modified Duke criteria for definite endocarditis. We analyzed demographic data, underlying conditions, clinical features, laboratory data, echocardiography, radiologic images, treatments, and outcomes. VO was diagnosed in 59 patients and IE was diagnosed in seven patients (12%). There were no significant differences in the clinical features, microorganisms, or radiographic status between the VO-IE co-infection and VO-only groups. In this study, using routine echocardiography for VO, the IE prevalence was 12%. The lack of specific clinical features and laboratory findings may hamper the diagnosis of IE. Therefore, clinicians are always required to suspect IE in patients with VO.Entities:
Keywords: co-infection; infective endocarditis; vertebral osteomyelitis
Year: 2022 PMID: 35456361 PMCID: PMC9030611 DOI: 10.3390/jcm11082266
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Previous reports of vertebral osteomyelitis and infective endocarditis co-infection.
| Author/Year | Department | Study Design | VO * Cases | VO-IE * Cases | Male | Age | IE Surgery | Mortality Rate |
|---|---|---|---|---|---|---|---|---|
| Ninet [ | Cardiology | Retrospective study | 150 | 9 (14) | 86 (12) | 56.6 | 29 | 7 |
| Morelli [ | Clinica Medica | Retrospective study | 30 | 10 (3) | 100 (3) | 48 | 67 | 0 |
| Le Moal [ | Internal Medicine and Infectious Diseases Department | Retrospective study | 92 | 15 (14) | 57 (8) | 69.1 ± 13.6 | 57 | 7 |
| Pigrau [ | Infectious Disease Department | Retrospective study | 91 | 31 (28) | 75 (21) | 66 ± 10.5 | 39 | 7 |
| Tamura [ | Cardiovascular Surgery | Retrospective study | 77 | 13 (11) | 72 (8) | 61.2 ± 11.7 | 55 | 0 |
| Akiyama [ | Orthopedic Surgery | Retrospective study | 6807 | 2 (145) | N/A | N/A | N/A | 12 |
| Koslow [ | Internal Medicine | Retrospective study | 62 | 23 (17) | 77 (13) | 70.6 ± 12.4 | 35 | 41 |
| Murillo [ | Infectious Diseases | Retrospective study | 202 | 21 (43) | N/A | N/A | N/A | N/A |
| Behmanesh [ | Neurosurgery | Prospective study | 110 | 33 (36) | 75 (27) | 70.3 ± 7.4 | 33 | 22 |
| Courjon [ | Infectious Disease Department | Retrospective study | 351 | 15 (51) | 69 (242) | N/A | N/A | N/A |
* VO, vertebral osteomyelitis; IE, infective endocarditis; N/A, not applicable.
Baseline characteristics of the VO-IE co-infection and VO-only groups.
| VO-IE * Co-Infection | VO *-Only | ||
|---|---|---|---|
| N = 7 (12%) | N = 52 (88%) | ||
| Demographic data | |||
| male | 5 (71%) | 39 (75%) | 0.84 |
| Age (median in years) | 76 ± 10.5 | 69 ± 12.4 | 0.32 |
| nosocomial infection | 1 (14%) | 8 (15%) | 0.94 |
| Underlying conditions | |||
| Diabetes mellitus | 1 (14%) | 15 (29%) | 0.91 |
| Neoplasm | 3 (43%) | 10 (19%) | 0.16 |
| Immunosuppression | 1 (14%) | 6 (12%) | 0.83 |
| Dialysis | 0 | 2 (4%) | 1.00 |
| Bad teeth hygiene | 1 (14%) | 4 (8%) | 0.56 |
| Cardiac comorbidities | 0 | 0 | (-) |
| Presumed source of the infection | |||
| Unknown | 4 (42%) | 41 (79%) | 0.34 |
| Skin and soft tissue | 1 (14%) | 1 (2%) | 0.09 |
| Pneumonia | 1 (14%) | 1 (2%) | 0.09 |
| Urinary tract | 1 (14%) | 5 (10%) | 0.7 |
| Digestive system | 0 | 1 (2%) | 1.00 |
| Odontogenic | 0 | 2 (4%) | 1.00 |
| Prosthetic knee | 0 | 1 (2%) | 1.00 |
| Clinical features | |||
| Back pain | 4 (57%) | 42 (81%) | 0.16 |
| Low back pain | 4 (57%) | 41 (79%) | 0.21 |
| Fever (>38 °C) | 4 (57%) | 23 (44%) | 0.52 |
| Laboratory data | |||
| Leukocytosis (K/µL) | 17.8 ± 4.2 | 11.9 ± 5.1 | 0.31 |
| Elevated C-reactive protein (mg/dL) | 16.2 ± 8.6 | 14.5 ± 7.5 | 0.18 |
| Echocardiography | |||
| Transthoracic echocardiography | 7 (100%) | 52 (100%) | 1.00 |
| Transesophageal echocardiography | 3 (43%) | 0 (0%) | 0.001 |
| Infected valve | |||
| Mitral valve | 1 (14%) | (-) | (-) |
| Aortic valve | 3 (43%) | (-) | (-) |
| Mitral and aortic valve | 1 (14%) | (-) | (-) |
| Mitral and tricuspid valve | 1 (14%) | (-) | (-) |
| IE Treatment | |||
| Conservative | 4 (57%) | (-) | (-) |
| Cardiac surgery | 3 (43%) | (-) | (-) |
| Valvuloplasty | 2 | ||
| Prosthetic replacement | 1 | ||
| In-hospital mortality | 1 (14%) | 0 (0%) | 0.006 |
* VO, vertebral osteomyelitis; IE, infective endocarditis.
Microbiological data of the VO-IE co-infection and VO-only groups.
| VO-IE * Co-Infection | VO *-Only | ||
|---|---|---|---|
| N = 7 (12%) | N = 52 (88%) | ||
|
| 6 (86%) | 43 (83%) | 0.84 |
|
| 7 (100%) | 49 (94%) | 0.51 |
| positive blood cultures | 6 (86%) | 23 (44%) | 0.05 |
| blood cultures (over two sets) | 7 (100%) | 42 (81%) | 0.2 |
|
| 7 (100%) | 43 (83%) | 0.23 |
| positive percutaneous needle biopsy and local excision at VO site, | 6 (86%) | 31 (72%) | 0.18 |
| positive percutaneous needle biopsy, | 3/4 (75%) | 14/23 (61%) | 0.6 |
| positive local excision, | 3/3 (100%) | 17/20 (85%) | 0.47 |
|
| |||
| Gram-positive | 4 (57%) | 33 (63%) | 0.75 |
| MSSA * | 2 | 12 | 0.75 |
| MRSA * | 1 | 6 | 0.83 |
| MRSE * | 0 | 2 | 0.6 |
|
| 1 | 1 | 0.83 |
| MRS/MSCNS * | 0 | 4 | 0.45 |
| 0 | 5 | 0.39 | |
|
| 0 | 1 | 0.71 |
|
| 0 | 2 | 0.6 |
| Gram-negative | 2 | 10 | 0.56 |
| 2 | 4 | 0.09 | |
|
| 0 | 3 | 0.51 |
|
| 0 | 1 | 0.71 |
|
| 0 | 1 | 0.71 |
|
| 0 | 1 | 0.71 |
* VO, vertebral osteomyelitis; IE, infective endocarditis; MSSA, Methicillin-susceptible Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; MRSE, Methicillin-resistant Staphylococcus epidermidis; MRS/MSCNS, Methicillin-resistant Staphylococcus/Methicillin-susceptible coagulase-negative Staphilococci.